Drug Trial Radar · NCT05211570
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
Aug 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Conditions
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions
AB8939Drug
Intravenous injection (from an initial dose of 0.9 mg/m²)
VenetoclaxDrug
the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of dose limiting toxicity (DLT)Time frame: Up to 56 days
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Institut Paoli Calmettes
Marseille, France · Not yet recruiting
National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit
Athens, Greece · Recruiting
General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante)
Alicante, Spain · Recruiting
Hospital San Pedro de Alcantara
Cáceres, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Quirónsalud
Madrid, Spain · Recruiting
MD Anderson Cancer Center Madrid
Madrid, Spain · Recruiting
Clínica Universidad de Navarra
Pamplona, Spain · Recruiting
Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío)
Seville, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.